ArticleJournal of veterinary internal medicine
Development of a reliable clinical assessment tool for meningoencephalitis in dogs: The neurodisability scale.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Clinical presentation, prognostic factors, and outcomes of meningoencephalitis of unknown origin in older dogs.Journal of veterinary internal medicine · 2026Article
- Epidural cell therapy reduces neurological sequelae severity in canine distemper survivors.Stem cell research & therapy · 2026Article
- Neurologic improvement and tumor shrinkage after radiotherapy in dogs with imaging-based intracranial neoplasia.Journal of veterinary internal medicine · 2026Article
- Retrospective evaluation of leflunomide as second-line immunosuppressive therapy in dogs with meningoencephalomyelitis of unknown origin: 18 cases (2018-2025).Journal of veterinary internal medicine · 2026Article
- Correlation between cerebellar lesion topography and differential diagnosis with clinical presentation in dogs.Journal of veterinary internal medicine · 2026Article
- Cerebrospinal fluid markers and magnetic resonance imaging lesion volume predicting relapse in canine meningoencephalitis of unknown origin.Frontiers in veterinary science · 2026Article
- Responsiveness of the neurodisability scale for meningoencephalitis of unknown origin in dogs.The Journal of small animal practice · 2025Article
- Usefulness of neurological assessment scales in prognosis of meningoencephalitis of unknown origin in Yorkshire Terriers.BMC veterinary research · 2025Article
- Comparison of 2.0 mg/kg/day and 0.5 mg/kg/day immunosuppressive dexamethasone protocols as initial treatment for dogs with MUO.Frontiers in veterinary science · 2025Article
- Of potential new treatment targets and polythetic approach in meningoencephalitis of unknown origin: a review.Frontiers in veterinary science · 2024Review
- Magnetic resonance imaging prognostic factors for survival and relapse in dogs with meningoencephalitis of unknown origin.Frontiers in veterinary science · 2024Article
- Allele frequency of a genetic risk variant for necrotizing meningoencephalitis in pug dogs from Europe and association with the clinical phenotype.Frontiers in veterinary science · 2024Article
- Evolution of Brain Magnetic Resonance Imaging Lesions in Dogs Treated for Meningoencephalomyelitis of Unknown Origin Between Initial Diagnosis and Relapse.Journal of veterinary internal medicineArticle
- Prognosis in meningoencephalitis of unknown origin in dogs: Risk factors associated with survival, clinical relapse, and long-term disability.Journal of veterinary internal medicineArticle
- Survival in dogs with meningoencephalomyelitis of unknown etiology with and without lesions detected by magnetic resonance imaging.Journal of veterinary internal medicineArticle
- Clinical features, treatment, and outcome of juvenile dogs with meningoencephalitis of unknown etiology.Journal of veterinary internal medicineArticle
- Comorbidities, long-term outcome and poststroke epilepsy associated with ischemic stroke - A multicenter observational study of 125 dogs.Journal of veterinary internal medicineArticle
- Development of a reliable clinical assessment tool for meningoencephalitis in dogs: The neurodisability scale.Journal of veterinary internal medicineArticle
- Brain Atrophy in Dogs With Meningoencephalitis of Unknown Origin.Journal of veterinary internal medicineArticle
- Comparison of Ultrasonographic Optic Nerve Sheath Diameter Before and After Mannitol Administration in Dogs With Presumed Intracranial Hypertension.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningoencephalitis of unknown origin (MUO) comprises a group of debilitating inflammatory diseases affecting the central nervous system of dogs. Currently, no validated clinical scale is available for the objective assessment of MUO severity.
objectivesDesign a neurodisability scale (NDS) to grade clinical severity and determine its reliability and whether or not the score at presentation correlates with outcome. ANIMALS: One hundred dogs with MUO were included for retrospective review and 31 dogs were subsequently enrolled for prospective evaluation.
methodsMedical records were retrospectively reviewed for 100 dogs diagnosed with MUO to identify the most frequent neurological examination findings. The NDS was designed based on these results and evaluated for prospective and retrospective use in a new population of MUO patients (n = 31) by different groups of independent blinded assessors, including calculation of interobserver agreement and association with outcome.
resultsThe most common clinical signs in MUO patients were used to inform categories for scoring in the NDS: seizure activity, ambulatory status, posture and cerebral, cerebellar, brainstem, and visual functions. The intraclass correlation coefficient (ICC) for prospective use of the NDS was 0.83 (95% confidence interval [CI], 0.68-0.91) indicating good agreement, and moderate agreement was found between prospective and retrospective assessors (ICC, 0.71; 95% CI, 0.56-0.83). No association was found between NDS score and long-term outcome. CONCLUSIONS AND CLINICAL IMPORTANCE: The NDS is a novel clinical measure for objective assessment of neurological dysfunction and showed good reliability when used prospectively in MUO patients but, in this small population, no association with outcome could be identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.